Last edition
News about " Oncology Pipeline with RIPTAC Platform"
Johnson & Johnson Acquires Halda Therapeutics to Strengthen Oncology Pipeline with RIPTAC Platform
Johnson & Johnson has completed the acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing oral, targeted therapies for solid tumours using its proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform. The transaction was completed for USD 3.05 billion in cash.
Oncology Pipeline With RIPTAC Platform | 31/12/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy